ABBOTT LABORATORIES — Director's Dealing 2020

Oct 28, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ABBOTT LABORATORIES (ABT)
CIK: 0000001800
Period of Report: 2020-10-26

Reporting Person: Funck Robert E (Executive Vice President & CFO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-10-26	Common shares without par value	M	83333	$38.40	Acquired	265550	Direct
2020-10-26	Common shares without par value	S	83333	$108.8279	Disposed	182217	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-10-26	Option (right to buy)	$38.40	M	83333	Disposed	2026-02-18	Common shares (83333)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common shares without par value	17702	Indirect
Common shares without par value	500	Indirect
Common shares without par value	500	Indirect

Footnotes

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.75 to $108.93, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F2: Balance in the Abbott Laboratories Stock Retirement Trust as of October 26, 2020.

F3: The reporting person disclaims beneficial ownership of all securities held by his daughter.

F4: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.